Genetic Engineering of Autologous Vein Grafts with thrombomodulin-Expressing Vectors to Resist thrombosis, Neointimal Hyperplasia and Atherosclerosis

Peak revenue. Peak revenue is shown only for cohort-consistency of the rNPV envelope and is NOT the decision criterion for this asset. A successful one-time ex-vivo graft pretreatment is a per-procedure adjunct (single-administration, no chronic dosing), and the most directly analogous program, edifoligide, was developed for this exact use case and never reached the market because it failed Phase 3 — so there is no real launched comparator to anchor a peak. The $150M figure is a deliberately conservative hypothetical per-procedure-adjunct ceiling against US/EU CABG and peripheral-bypass volumes at modest device-adjunct-like pricing; it is illustrative, not a forecast, consistent with the grant_non_commercial classification.

WACC. A 16% rate reflects elevated risk above a standard biologic (12–13%): a transient adenoviral ex-vivo modality, an acquired (non-genetic) target rationale, expired underlying IP, and a directly analogous ex-vivo graft-modification category with a completed negative Phase 3 (PREVENT III/IV).

This asset is a 1999 Johns Hopkins disclosure (Case C03579, report date July 1999) describing adenoviral ex-vivo/in-vivo gene transfer of thrombomodulin into autologous vein grafts to resist the three temporal failure modes of bypass conduits — acute thrombotic occlusion, subacute neointimal hyperplasia, and late atherosclerosis. The underlying biology is real and elegant: the Hopkins group showed thrombomodulin expression collapses >95% in the first two weeks after a vein is grafted into the arterial circulation, removing a key endothelial anticoagulant exactly when the conduit is most thrombogenic. It is classified grant_non_commercial: it is a genuine therapeutic concept, not a research tool, but it is a quarter-century-old disclosure with no disclosed patents (any utility filing from ~1999 has long since expired) and — critically — the inventors' own Circulation Research 2002 data show TM restoration reduced bound thrombin activity but did NOT affect neointima formation, directly undercutting two of the three benefits in the patent title.

There is no live commercial comparator to anchor a forecast because the most clinically advanced asset in this exact modality, edifoligide — a one-time ex-vivo oligonucleotide graft pretreatment — failed Phase 3 in BOTH coronary (PREVENT IV, 3,014 patients) and peripheral (PREVENT III, 1,404 patients) bypass, with no clinical benefit at 5 years and a safety signal. The economic frame is therefore not a product DCF but a cautionary-precedent frame: the registrational bar is a large multicenter angiographic-endpoint trial against a category that already failed it, on a transient adenoviral vector against an acquired, mechanotransduction-driven target. The engine result is -$43.1M to -$25.4M, with a base rNPV of -$34.2M and cumulative PoS of 0.5%; that spread is shown only for cohort consistency — the rNPV is not the decision criterion here, which is why the asset is classified grant_non_commercial, and the realistic path is academic follow-on or a non-commercial vascular-biology contribution, not standalone equity.

Verdict: a biologically interesting, historically important, but commercially non-viable disclosure. It earns its rubric rank from a strong modality_pos (gene_therapy bucket) plus the neutral 0.5 whitespace of an "other" cardiovascular indication and high IRA-exposure subscore — not from being a fundable product. The honest classification is grant_non_commercial because expired IP, a definitive negative same-modality Phase 3 precedent, and the inventors' own no-neointima-benefit data jointly eliminate the standalone-equity case while leaving residual scientific value.